Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Conatus Pharmaceuticals Inc.    CNAT

CONATUS PHARMACEUTICALS INC.

(CNAT)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
0.443(c) 0.4365(c) 0.436(c) 0.435(c) 0.4657(c) Last
305 837 292 259 292 951 339 966 910 979 Volume
+0.68% -1.47% -0.11% -0.23% +7.06% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 15,4 M
More Financials
Company
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing... 
More about the company
Latest news on CONATUS PHARMACEUTICALS IN
02/06CONATUS PHARMACEUTICALS : Histogen to Present at BIO CEO & Investor Conference
PR
01/30CONATUS PHARMACEUTICALS : Histogen and Allergan Expand Cell Conditioned Media (C..
PR
01/28CONATUS PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Chang..
AQ
01/28Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement
GL
2019CONATUS PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement (form ..
AQ
2019CONATUS PHARMACEUTICALS INC. : Notice of Delisting or Failure to Satisfy a Conti..
AQ
2019CONATUS PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8..
AQ
2019Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member
GL
2019CONATUS PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8..
AQ
2019CONATUS : 3Q Earnings Snapshot
AQ
2019CONATUS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
2019CONATUS PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fi..
AQ
2019Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results
GL
2019CONATUS PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Termi..
AQ
2019CONATUS PHARMACEUTICALS INC. : Costs Associated with Exit or Disposal Activities..
AQ
More news
News in other languages on CONATUS PHARMACEUTICALS IN
2019CONATUS PHARMACEUTICALS INC : publication des résultats annuels
2019CONATUS PHARMACEUTICALS INC : Veröffentlichung des Jahresergebnisses
2019STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
2018L'Europe finit en hausse, les annonces de la Fed pour 2019 attendues
2015Les valeurs à suivre Sur les marchés américains
More news
Analyst Recommendations on CONATUS PHARMACEUTICALS IN
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart CONATUS PHARMACEUTICALS IN
Duration : Period :
Conatus Pharmaceuticals In Technical Analysis Chart | CNAT | US20600T1088 | MarketScreener
Technical analysis trends CONATUS PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsNeutralBullishBearish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,47  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Steven J. Mento President, Chief Executive Officer & Director
David F. Hale Chairman
Keith W. Marshall Executive VP, Chief Operating & Financial Officer
Alfred P. Spada CSO, Executive VP-Research & Development
Harold E. van Wart Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CONATUS PHARMACEUTICALS INC.16.43%15
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB A/S14.61%16 125